Reference is made to the stock exchange announcement by Navamedic ASA (the “Company”) on 27 February 2019 regarding the Company’s completion of the acquisition of Novicus Pharma AS and issuance of 1,000,000 new shares in the Company as consideration to the sellers of Novicus Pharma AS.

The share capital increase pertaining to the share issuance has now been registered with the Norwegian Register of Business Enterprises. The Company’s new registered share capital is NOK 11,867,673, divided on 11,867,673 shares, each with a nominal value of NOK 1.

For further information, please contact:
Toril Ås Chief Financial Officer (CFO)
Navamedic ASA
Tel: +47 95 70 10 71
E-mail: toril.as@navamedic.com

This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.